Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Diltiazem drug class?
How does iron rich food intake impact lipitor's efficacy?
Dabrafenib patent expiration date novartis gsk composition matter?
Patent expiration date of guselkumab?
Alogliptin benz cost?

Qelbree approval?

See the DrugPatentWatch profile for Qelbree

Qelbree (viloxazine hydrochloride) – FDA Approval Timeline

Date Indication Notes
May 2021 ADHD in children and adolescents aged 6‑17 First non‑stimulant ADHD drug approved by the FDA since 2017.
September 2022 ADHD in adults aged 18‑64 Extends use to the adult population.

Key Points

Aspect Details
Drug class Non‑stimulant, selective norepinephrine reuptake inhibitor (SNR).
Mechanism Increases norepinephrine signaling in the prefrontal cortex, improving attention, impulse control, and hyperactivity.
Dosage Started at 50 mg once daily; titrated up to 100 mg, then to 200 mg, based on tolerance and response.
Common side effects Headache, insomnia, fatigue, nausea, decreased appetite.
Contraindications Severe hepatic impairment, hypersensitivity to viloxazine, use of MAO‑I within 14 days.
Drug interactions Caution with CYP1A2 inhibitors/inducers; avoid concurrent use with MAO inhibitors.

Why It Matters

  • Non‑stimulant option: Provides an alternative for patients who cannot tolerate or wish to avoid stimulant medications (e.g., methylphenidate, amphetamines).
  • Safety profile: Generally well‑tolerated with lower risk of cardiovascular side effects compared to stimulants.
  • First‑in‑class: Offers a new therapeutic mechanism for ADHD that targets noradrenergic pathways rather than dopaminergic pathways predominant in stimulants.

Regulatory Context

  • United States: FDA approval as above.
  • European Union: Not yet approved (EMA review ongoing as of 2026).
  • Other regions: Some countries (e.g., Canada, Australia) have pending or recent approvals; check local regulatory authorities.

Clinical Use

  • Typically initiated when stimulants are contraindicated, ineffective, or poorly tolerated.
  • Can be used as monotherapy or adjunct to stimulants.
  • Monitoring for growth suppression, blood pressure, heart rate is recommended, especially in pediatric patients.

Bottom Line:
Qelbree received FDA approval first in May 2021 for adolescents and children 6‑17 with ADHD, and then in September 2022 for adults 18‑64. It’s the first non‑stimulant ADHD drug approved by the FDA in over five years, offering an alternative mechanism and safety profile for patients needing ADHD treatment.



Other Questions About Qelbree :

Fda approval qelbree adhd? Side effects of qelbree in kids? Qelbree fda prescribing information? Generic for qelbree? Qelbree adhd? Qelbree fda prescribing information pdf? Qelbree fda approval for adults date?